Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease.
JACC Basic Transl Sci
; 7(9): 956-969, 2022 Sep.
Article
em En
| MEDLINE
| ID: mdl-36317129
ABSTRACT
Cardiovascular disease (CVD) remains the largest cause of mortality worldwide. The development of new effective therapeutics is a major unmet need. The current review focuses broadly on the concept of nucleic acid (NA)-based therapies, considering the use of various forms of NAs, including mRNAs, miRNAs, siRNA, and guide RNAs, the latter specifically for the purpose of CRISPR-Cas directed gene editing. We describe the current state-of-the-art of RNA target discovery and development, the status of RNA therapeutics in the context of CVD, and some of the challenges and hurdles to be overcome.
AAV, adeno-associated viral vector; ASO, antisense oligonucleotide; CRISPR, clustered regularly interspaced short palindromic repeats; CVD, cardiovascular disease; DMD, Duchenne muscular dystrophy; HF, heart failure; NA, nucleic acid; RNA; cardiovascular disease; circRNA, circular RNA; lncRNA, long noncoding RNA; miRNA, microRNA; ncRNA, noncoding RNA; noncoding RNA; nucleic acid-based therapies; therapeutic modalities
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
JACC Basic Transl Sci
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos